Guangze Li

Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [14C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase

D. Zhong, L. Miao, Yan Zhan, 2021, Drug Metabolism and Disposition.

Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP‐ribose) polymerase inhibitor, in subjects with advanced solid cancers

D. Zhong, Linsheng Liu, Chenrong Huang, 2022, British journal of clinical pharmacology.

Tomato based gelatin methacryloyl hydrogel as an effective natural and low-cost scaffold for accelerative wound healing.

Tianqi Nie, Chunlin Huang, Guangze Li, 2022, International journal of biological macromolecules.

Mechanistic Study on the Species Differences in Excretion Pathway of HR011303 in Humans and Rats

Xiaoyan Chen, D. Zhong, Yaru Xue, 2021, Drug Metabolism and Disposition.

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

H. Rugo, B. Shao, Huiping Li, 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans

D. Zhong, Yi-cong Bian, Yan Zhan, 2023, Frontiers in Pharmacology.